UroGen's ZUSDURI Shows Long-Term Efficacy in Non-Muscle Invasive Bladder Cancer

UroGen Pharma announced the publication of five-year long-term extension study results from the Phase 2b OPTIMA II trial. The study evaluated ZUSDURI...